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Abstract. Mesenchymal stem cells (MSCs) differentiate 
into multiple lineages and are a promising source of cells for 
clinical use. Previously, we found that the gene distal-less 
homeobox 5 (DLX5) is specifically expressed in MSCs 
with osteogenic potential. Understanding the mechanism of 
osteogenesis is necessary for successful bone regeneration 
using MSCs. The aim of this study was to examine the func-
tion of the DLX5 gene in MSCs during osteogenesis (bone 
development). We analyzed the possible association between 
DLX5 expression and osteogenesis-, chondrogenesis- and 
adipogenesis-related gene expression in different cells isolated 
from bone marrow and cord blood. Differentiation capacity 
was assessed by observing morphological changes, moni-
toring gene expression patterns, and staining with Von Kossa, 
safranin O, and Oil Red O. Suppression of DLX5 expression 
by means of a small interfering RNA (siRNA) downregulated 
osteogenic markers and reduced the signs of calcium mineral-
ization. Tanshinone IIA is a known small molecule activator 
of bone morphogenetic protein (BMP) signaling. Here, we 
report that induction of DLX5 by tanshinone IIA in MSCs 
enhanced osteogenic differentiation. In addition, we showed 
that tanshinone IIA (as a mediator of BMP2 signaling) acti-
vates runt-related transcription factor 2 (RUNX2) in MSCs and 
initiates calcium mineralization during osteogenesis. Taken 
together, these findings indicate that, in MSCs, DLX5 is a 
master regulator of osteogenesis. Furthermore, tanshinone IIA 
may be valuable for stem cell-based therapies of certain bone 
diseases.
Introduction
Mesenchymal stem cells (MSCs) derived from various sources 
are valuable in regenerative medicine, including bone repair, 
because they can differentiate into multiple cell lineages, 
including osteoblasts, chondrocytes and adipocytes (1,2). 
MSCs derived from different tissues have similar character-
istics, but differ in their molecular profiles and differentiation 
potential (3).
Recently, MSCs have been applied to bone tissue engi-
neering with a regenerative medicine approach (4). Osteogenic 
differentiation of MSCs is intricately regulated by multiple 
transcription factors and various cytokines and hormones (5-7). 
Previously, we found that distal-less homeobox 5 (DLX5), a 
homeodomain transcription factor encoded by a mammalian 
homolog of one of the Drosophila distal-less (DLL/DLX) 
genes that regulates the development of multiple cell types, 
is only expressed in MSCs with osteogenic potential (3). 
The discovery led us to examine whether DLX5 is critically 
involved in the differentiation of MSCs into osteoblasts.
Homeobox-containing genes play a key role as regula-
tors of skeletal development (8). DLX genes that encode 
homeobox-containing transcription factors function in 
several developmental processes, including osteoblast devel-
opment (9,10). DLX5, which is involved in developing bone, 
cartilage, and teeth, is a member of the distal-less homeobox 
domain family (11-14). Overexpression of DLX5 is known to 
stimulate bone differentiation, and DLX5-null mice exhibit 
abnormal osteogenesis (15-18). Although numerous studies 
strongly suggest that DLX5 is involved in osteogenesis, its 
functional role in this process is still obscure.
Here, we investigated the regulatory role of DLX5 in osteo-
genic differentiation of bone marrow- and cord blood-derived 
MSCs by examining the effects of DLX5 inhibition and the 
expression levels of osteogenesis-associated genes, including 
bone morphogenetic protein 2 (BMP2) and runt-related tran-
scription factor 2 (RUNX2). BMP2 and RUNX2 play essential 
roles in bone development and maintenance by collaborating 
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with other signaling molecules; however, they are insufficient 
to induce osteogenic differentiation (19,20).
The aim of this study was to examine the key regulators of 
osteogenesis in MSCs. DLX5 is regulated by BMP2, an inducer 
of osteogenesis (21,22). To investigate the effects of DLX5 on 
osteogenic differentiation of MSCs, we examined osteogenic 
factors (DLX5 and RUNX2), chondrogenic factors [BMP7 
and sex determining region Y-box 9 (SOX9)], and adipogenic 
factors [peroxisome proliferator-activated receptor γ (PPARG) 
and CCAAT-enhancer binding protein α (C/EBPA)]. We 
demonstrated that the induction of DLX5 led to osteoblast 
differentiation with the expression of several osteoblast 
markers, whereas the knockdown of DLX5 expression inhib-
ited the osteogenesis of MSCs. Our data indicate that DLX5 
is the master transcription factor stimulating the osteogenic 
factor RUNX2 through BMP2 signaling during osteogenesis.
Furthermore, we aimed to ascertain whether activation 
of DLX5 and/or BMP2 signaling by certain chemicals could 
induce osteogenic differentiation in MSCs. Tanshinone IIA 
is a major active phytochemical derived from phenanthren-
equinone, which can be isolated from the roots of Salvia 
miltiorrhiza. It was found to enhance BMP2-stimulated differ-
entiation of C2C12 cells into osteoblasts via p38 activation (23). 
For the first time, we evaluated the effect of tanshinone IIA 
on the differentiation of MSCs into osteoblasts. This study 
demonstrated that tanshinone IIA affects osteogenesis from 
MSCs by augmenting DLX5.
These findings may be important for regenerative medicine, 
facilitating an increase in MSCs with osteogenic potential. 
Further, tanshinone IIA, as a small-molecule activator of 
DLX5 and BMP signaling, could be one of the key molecules 
in DLX5-induced osteogenesis of MSCs.
Materials and methods
Cells. Bone marrow and umbilical cord blood were collected 
from healthy donors after obtaining written informed consent. 
This study was approved by the Institutional Review Boards of 
Severance Hospital of Yonsei University Health System, Seoul, 
Korea. As previously described, mononuclear cells were isolated 
by Ficoll-Hypaque density gradient centrifugation (Pharmacia 
Biotech, Uppsala, Sweden) and the MSCs were cultured using 
the plastic adherence method (24). The cells were cultured 
at 37˚C with 5% CO2, and the medium [DMEM-low glucose 
supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin (P/S) (all from Invitrogen, Carlsbad, 
CA, USA)] was changed every 3 or 4 days. Tanshinone IIA 
from Sigma-Aldrich (St. Louis, MO, USA) was used for this 
study. During cultivation, cells were photographed under an 
inverted phase microscope (Olympus IX-71; Olympus, Tokyo, 
Japan) to compare morphologies.
Differentiation. To cause MSCs to differentiate into osteo-
blasts, chondrocytes, and adipocytes, bone marrow- and cord 
blood-derived MSCs were cultured in osteogenic induction 
medium, chondrogenic induction medium, and adipogenic 
induction medium for 3 weeks (Cambrex, Lonza, MD, USA). 
Osteoinductive medium-treated cells were used as the control. 
The medium was changed every 3 or 4 days, and the cells 
intended for chondrogenic differentiation were treated with 
10 ng/ml transforming growth factor (TGF)-β3 (Cambrex) 
whenever the medium was replaced. For analysis, the induced 
cells were stained by Von Kossa to confirm osteogenesis, 
safranin O to confirm chondrogenesis, and Oil Red O to confirm 
adipogenesis. Images of the stained cells were captured using 
a phase microscope (Olympus IX-71; Olympus).
RT-PCR. Total RNA was extracted using TRIzol reagent, and 
standard reverse transcription (RT) was carried out using tran-
scriptase II (both from Invitrogen). RT-PCR was performed 
using PCR primers (Bioneer, Daejeon, Korea) and annealing 
temperatures listed in Table I. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as an internal control. The 
signal intensity of the product was normalized to the respec-
tive GAPDH signal intensity. Osteoinductive medium-treated 
cells were used as control.
Small interfering RNA (siRNA) gene silencing. Specific 
knockdown of gene expression was performed using siRNA 
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA) specific 
for DLX5. Briefly, 2x105 MSCs were transfected with 10 µM 
of negative control or targeted siRNA according to the manu-
facturer's protocol. Following incubation for 7 h at 37˚C and 
5% CO2, normal growth medium was added. After one day, 
medium was replaced with fresh normal growth medium. 
The effect of gene knockdown by siRNA was evaluated by 
RT-PCR assay. MSCs were treated with DLX5-siRNA when 
medium was replaced for the entire induction period.
Cell viability test. The viability of chemically treated cells was 
analyzed by the trypan blue exclusion method (Invitrogen). 
Briefly, cells were seeded at a density of 5x104 cells in 12-well 
plates (Nunc, Roskilde, Denmark). The next day, 3, 6, 12, 24 or 
48 µM of tanshinone IIA was added to the cells. After 3 days, 
the cells were harvested and trypan blue-stained cells were 
counted.
Analysis of calcium concentration. Following osteogenic 
induction, the calcium content of cells was determined 
using a Calcium (CPC) LiquiColor Test (Stanbio Laboratory, 
Boerne, TX, USA) according to the manufacturer's instruc-
tions. Briefly, the cells were washed with phosphate-buffered 
saline (PBS; Invitrogen) and 0.5 N HCl was added to the cells. 
The cells were harvested and transferred to a new tube. After 
shaking for 3 h with an orbital shaker, the supernatant was 
transferred to a new tube for analysis. Color and base reagents 
were added to the supernatant, and then absorbances were 
detected at 550 nm. The cells cultured in DMEM were used 
as the control.
Statistical analysis. Quantitative data are expressed as the 
means ± standard deviation (SD). Statistical comparisons 
were performed by a Student's t-test and one-way analysis of 
variance (ANOVA) with post-hoc Bonferroni corrections. The 
differences were considered statistically significant at P<0.05.
Results
Characterization of bone marrow- and cord blood-derived 
MSCs. All MSCs derived from bone marrow and cord blood 
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showed a similar spindle-shaped morphology (Fig. 1A). 
Surface markers of the MSCs were analyzed, and the results 
showed that all cells exhibited similar immunophenotypic 
patterns. The cells were positive for CD29, CD44, CD73, 
CD90 and CD105, all known markers of MSCs, whereas the 
MSCs were negative for markers of endothelial and hemato-
poietic cells such as CD14, CD31, CD34, CD45 and CD106 
(data not shown). These results confirmed that the cultured 
cells expressed typical MSC surface markers. To determine 
their differentiation capacity, the cells were induced to 
display osteogenic, chondrogenic, or adipogenic phenotypes. 
Of the MSCs derived from bone marrow and cord blood, 
one sample of cord blood MSCs (CB-MSC1) did not differ-
entiate into osteoblasts despite a sufficient induction period, 
whereas the other MSCs exhibited tri-lineage differentiation 
potential, developing into osteoblasts, chondrocytes and 
adipocytes (Fig. 1B). Together, these data indicate that not 
all MSCs with fibroblast-like morphologies and MSC surface 
proteins have tri-lineage differentiation capacities.
Osteogenesis and DLX5 expression of MSCs. To investigate 
osteogenic molecular profiles associated with morphological 
changes, we performed an RT-PCR analysis of specific osteo-
genesis markers, namely BMP2, RUNX2 and DLX5, during the 
induction of bone marrow- and cord blood-derived MSCs from 
different donors. BMP2, RUNX2 and DLX5 were expressed 
in all MSCs that differentiated into osteoblasts, regardless of 
the induction period (Fig. 2). However, CB-MSC1, which did 
not differentiate into an osteogenic phenotype, did not express 
BMP2 and DLX5 at any time in the induction environment. 
Interestingly, RUNX2 was independently expressed in all 
MSCs, regardless of their osteogenic potential (Fig. 2). These 
results coincide with previous data, confirming DLX5 as a 
marker for the osteogenic potential of MSCs (3). Based on 
these results, we noted that DLX5 with BMP2 signaling may 
be the only critical factors for osteogenesis of MSCs.
Effect of DLX5 knockdown on the differentiation potential 
of MSCs. To examine the role of DLX5 in the tri-lineage 
Table I. Primer sequences.
Gene Primer sequences Annealing Product
name (5'-3') temperature (˚C) size (bp)
BMP2 Forward: CGAGGTCCTGAGCGAGTTCGAG
 Reverse: TGGCAGTAAAAGGCGTGATACC 60 838
RUNX2 Forward: GACCAGTCTTACCCCTCCTACC
 Reverse: CTGCCTGGCTCTTCTTACTGAG 58 190
DLX5 Forward: ACCATCCGTCTCAGGAATCG
 Reverse: ACCTTCTCTGTAATGCGGCC 60 384
GAPDH Forward: GTGGTCTCCTCTGACTTCAACA
 Reverse: CTCTTCCTCTTGTGCTCTTGCT 62 210
BMP7 Forward: CCAACGTCATCCTGAAGAAATAC
 Reverse: GCTTGTAGGATCTTGTTCATTGG 60 271
SOX9 Forward: GCCGGGCAAGGCTGACCTGAAG
 Reverse: TTCTGGTGGTCGGTGTAGTCGT 62 605
PPARG Forward: TCTCTCCGTAATGGAAGACC
 Reverse: GCATTATGAGACATCCCCAC 55 474
C/EBPA Forward: CCAAGAAGTCGGTGGACAAGAA
 Reverse: TCATTGTCACTGGTCAGCTCCA 62 145
Osterix Forward: TAATGGGCTCCTTTCACCTG
 Reverse: CACTGGGCAGACAGTCAGAA 60 161
Osteopontin Forward: GAGACCCTTCCAAGTAAGTCCA
 Reverse: GATGTCCTCGTCTGTAGCATCA 62 354
Type I collagen Forward: CACAGAGGTTTCAGTGGTTTGG
 Reverse: GCACCAGTAGCACCATCATTTC 62 191
AP2 Forward: AAGAAGTAGGAGTGGGCTTTGC
 Reverse: CCACCACCAGTTTATCATCCTC 62 381
BMP2, bone morphogenetic protein; RUNX2, runt-related transcription factor 2; DLX5, distal-less homeobox 5; GAPDH, glyceral-
dehyde 3-phosphate dehydrogenase; SOX9, sex determining region Y-box 9; PPARG, peroxisome proliferator-activated receptor γ; 
C/EBPA, CCAAT-enhancer binding protein α.
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Figure 1. Morphology and differentiation potential of mesenchymal stem cells (MSCs). (A) Phase contrast images of MSCs derived from bone marrow and cord 
blood (scale bar, 100 µm; magnification, x200). (B) Differentiation capacity was examined after induction. Osteogenesis was verified by Von Kossa staining 
(scale bar, 100 µm; magnification, x200). Chondrogenesis was investigated by safranin O staining (scale bar, 100 µm; magnification, x200). Adipogenesis was 
examined by Oil Red O staining (scale bar, 50 µm; magnification, x400).
Figure 2. Time course images of osteogenic differentiation and expression of osteogenesis-related markers. Top panels: images of BM-MSC1 induced by 
osteogenic medium, and RT-PCR analysis of osteogenesis-associated markers in BM-MSC1. Second row: images of BM-MSC2 differentiated by osteogenic 
medium, and RT-PCR analysis of osteogenesis-related markers in BM-MSC2. Third row: images of CB-MSC1 induced by osteogenic medium, and RT-PCR 
analysis of osteogenesis-associated markers in CB-MSC1. Lower panels: images of CB-MSC2 induced by osteogenic medium, and RT-PCR analysis of 
osteogenesis-related markers in CB-MSC2. Osteogenesis was evaluated by Von Kossa staining (scale bar, 100 µm; magnification, x200).
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  40:  1486-1494,  20171490
differentiation of MSCs, we employed siRNA-mediated 
knockdown of DLX5, using DLX5-expressing cells. The 
morphologies of cultured MSCs before induction were 
unaffected, compared to those of the control, by short-term 
treatment with DLX5-siRNA (Fig. 3A). RT-PCR results 
showed that DLX5-siRNA substantially decreased expression 
of the DLX5 gene and completely silenced the osteogenic 
marker gene RUNX2 and chondrogenic marker gene SOX9. 
C/EBPA of the adipogenic marker genes was unaffected by 
DLX5-siRNA treatment, while PPARG expression was slightly 
decreased (Fig. 3B). These results indicate that osteogenesis of 
MSCs can be markedly affected by DLX5-siRNA knockdown.
We next performed a differentiation assay in the presence 
of DLX5-siRNA. Surprisingly, the osteogenic capacity of 
MSCs treated with DLX5-siRNA was significantly decreased, 
whereas chondrogenic and adipogenic capacities were similar, 
relative to that of the control, although MSCs did not express 
the SOX9 gene following DLX5-siRNA treatment (Fig. 3C). 
We then analyzed gene expression levels related to tri-lineage 
differentiation by RT-PCR after induction. Expression of the 
following genes was evaluated: DLX5, RUNX2, BMP2 and 
osteopontin for osteogenesis; DLX5, BMP7, SOX9 and type I 
collagen for chondrogenesis; and DLX5, PPARG, C/EBPA and 
AP2 for adipogenesis. The levels of RUNX2 and osteopontin 
gene expression were significantly decreased relative to the 
control by inhibition of DLX5 (Fig. 3D), whereas no significant 
differences were detected in the expression of chondrogen-
esis- (Fig. 3E) or adipogenesis- (Fig. 3F) related genes. Relative 
gene expression was normalized to that of GAPDH, the internal 
control. These results strongly suggest that DLX5 is the most 
powerful and specific transcription factor for osteogenic differ-
entiation.
Tanshinone IIA induces DLX5 through BMP2 signaling 
in MSCs. Tanshinone IIA, a major active phytochemical, 
is involved in bone metabolism. It has a wide range of 
biological activities, including anti-inflammation and anti-
oxidation (25-27). Moreover, tanshinone IIA is known to 
Figure 3. Changes in mesenchymal stem cells (MSCs) following knockdown of distal-less homeobox 5 (DLX5). (A) Phase contrast images before and after 
silencing of DLX5 (scale bar, 200 µm; magnification, x100). (B) RT-PCR analysis of osteogenesis-, adipogenesis- and chondrogenesis-associated genes in the 
control and DLX5 siRNA-transfected MSCs. Decreased osteogenic differentiation of MSCs following knockdown of DLX5. (C) Inhibition of DLX5 expres-
sion prevents osteogenesis of MSCs. The differentiation capacity of MSCs was analyzed after induction. (a) Osteogenesis assessed by Von Kossa staining. 
(b) Chondrogenesis assessed by safranin O staining. (c) Adipogenesis assessed by Oil Red O staining (scale bar, 100 µm). Relative mRNA expression levels 
of differentiation-associated markers in the control and DLX5-siRNA-transfected MSCs after (D) osteogenic induction, (E) chondrogenic induction, and 
(F) adipogenic induction. *P<0.05.
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enhance BMP-2 stimulation of cells to differentiate into osteo-
blasts (23). Ultimately, stimulation by tanshinone IIA induces 
osteogenesis via regulation of osteogenic factors, including 
BMP2 and DLX5.
Therefore, we tested whether tanshinone IIA could induce 
DLX5 in DLX5 not-expressing MSCs. Cell morphologies 
were not affected by 3, 6, 12, 24 or 48 µM of tanshinone IIA 
treatment (Fig. 4A). In addition, cell viability of >90% 
was maintained with tanshinone IIA treatment (Fig. 4B). 
Remarkably, BMP2, DLX5 and osterix genes were only 
induced in response to 6 µM of tanshinone IIA treatment, as 
early as after 3 days of cultivation, indicating the activation of 
DLX5 by the BMP2 pathway. However, RUNX2 was similarly 
expressed (Fig. 4C). Taken together, these results show that 
tanshinone IIA can induce DLX5, as well as the most promi-
nent factors of osteogenesis.
Tanshinone IIA enhances osteogenesis of MSCs by inducing 
DLX5 with BMP2. We next treated DLX5 not-expressing 
MSCs with 6 µM tanshinone IIA to induce osteogenesis. After 
tanshinone IIA treatment, we did not find any differences in 
our morphological investigation. Subsequently, the effect of 
tanshinone IIA on the osteogenic potential of MSCs was eval-
uated by analyzing the expression levels of genes associated 
with osteogenic differentiation and by visualizing the staining 
of induced cells. Tanshinone IIA significantly induced BMP2 
and DLX5, as well as upregulated RUNX2 genes involved in 
osteogenesis. The expression of SOX9, which is involved in 
chondrogenesis, was similarly upregulated, compared to that 
of the control, despite tanshinone IIA treatment, whereas 
BMP7 expression was decreased (Fig. 5A). Interestingly, 
expression of C/EBPA, a transcription factor for adipogenesis, 
was completely inhibited by tanshinone IIA (Fig. 5A). The 
differentiation assay revealed that tanshinone IIA specifically 
enhanced osteogenesis of MSCs (Fig. 5B). This finding was 
confirmed by calcium deposition assay, as shown in Fig. 5C. 
Furthermore, tanshinone IIA-mediated enhancement of DLX5 
through the induction of BMP2 upregulated mRNA expression 
of RUNX2 and osteopontin during osteogenic differentiation 
of MSCs (Fig. 5D). As shown in Fig. 5A, we again confirmed 
that the expression of BMP7 was decreased significantly 
during chondrogenesis (Fig. 5E), and that C/EBPA expres-
sion was suppressed by tanshinone IIA during adipogenic 
differentiation (Fig. 5F). Relative gene expression in the 
differentiated MSCs was normalized to GAPDH, the internal 
control. Surprisingly, tanshinone IIA-treated MSCs differenti-
ated into chondrocytes and adipocytes despite the suppression 
of BMP7 and C/EBPA genes (Fig. 5B). Taken together, these 
results indicate that tanshinone IIA induces osteogenesis 
in DLX5 not-expressing MSCs by activating DLX5 through 
BMP2 expression.
Discussion
MSCs derived from various tissues have become a preferred 
cell type in the field of regenerative medicine due to their 
plastic and immunosuppressive properties (28). Although stem 
cells hold great promise for future therapeutic applications, 
clinical applications using these cells have been stymied by an 
insufficient understanding of stem cell biology, including the 
complex genetic processes in these cells. Therefore, further 
characterization of stem cells via diverse approaches such as 
genomics and proteomics will be critical for a better under-
standing and utilization of stem cells.
Figure 4. Effect of tanshinone IIA on osteogenesis. (A) Mesenchymal stem cells (MSCs) treated with tanshinone IIA were photographed after 3 days (scale 
bar, 200 µm; magnification, x100). (B) Cell viability was determined by trypan blue staining. The cell viability of the tanshinone IIA-treated MSCs was >90%. 
(C) Induction of osteogenesis-associated genes by tanshinone IIA treatment. Treatment only with 6 µM tanshinone IIA induced BMP2, distal-less homeobox 5 
(DLX5) and osterix genes.
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Previous research on MSCs from different sources has 
documented their variable differentiation potential and has 
shown that this variation in osteogenic potential depends on 
DLX5 gene expression (3). Consistent with the results of a 
previous study, DLX5 expression was not detected in MSCs 
that did not have the capacity to differentiate into osteoblasts. 
In addition, BMP2 gene expression was not observed in this 
study when DLX5 not-expressing MSCs were maintained 
in an osteogenic environment. Differentiation of stem cells 
is a complex process governed by various genetic networks, 
and the biological functions of genes associated with MSC 
differentiation remain unclear. In the present study, we aimed 
to investigate the precise role of the DLX5 gene during the 
osteogenesis of MSCs, including whether the DLX5 gene is 
important for initiating osteogenesis and whether the gene is 
sufficient to completely drive osteogenesis from MSCs.
DLX5, a member of the DLX family of homeobox genes, is 
known to be a key regulator of differentiation involved in devel-
oping skeletal elements and of osteogenesis and chondrogenesis 
in the formation of hard tissues (29). Several studies suggest 
that DLX5 acts as a modulator of osteogenesis in various cell 
types (18,30). However, the mechanism underlying osteogenic 
differentiation, including the role of DLX5, is still controver-
sial, especially in MSCs. In this study, we used MSCs derived 
from bone marrow and cord blood, less than 5 passages, and 
expressing and/or not expressing the DLX5 gene to identify the 
effects, including the effects on genes activated and inactivated 
by DLX5 in the course of differentiation. In order to investi-
gate the role of DLX5, we profiled morphological and gene 
expression changes associated with osteogenesis of MSCs. As 
mentioned above, DLX5 not-expressing MSCs without BMP2 
expression failed to differentiate into osteoblasts. However, 
RUNX2 was consistently expressed during osteogenic induc-
tion, irrespective of the expression of BMP2 and DLX5. To 
further examine the effect of DLX5 on osteogenesis, siRNA, 
which targets the DLX5 gene, was used to inhibit endogenous 
DLX5 expression in MSCs. Knockdown of DLX5 using siRNA 
did not alter the morphology and the proliferation rate of the 
cells. Seventy-two hours after siRNA transfection, RUNX2 
and SOX9 genes specific for osteogenesis and chondrogenesis, 
Figure 5. Changes in mesenchymal stem cells (MSCs) following tanshinone IIA treatment. (A) RT-PCR analysis of osteogenesis-, chondrogenesis- and adi-
pogenesis-associated genes in the control and tanshinone IIA-induced MSCs. Increased osteogenic differentiation of MSCs by tanshinone IIA. (B) Induction 
of distal-less homeobox 5 (DLX5) expression enhanced osteogenesis of DLX5 not-expressing MSCs. The differentiation capacity of the cells was analyzed 
after induction. (a) Osteogenesis assessed by Von Kossa staining (scale bar, 50 µm). (b) Chondrogenesis assessed by safranin O staining (scale bar, 100 µm). 
(c) Adipogenesis assessed by Oil Red O staining (scale bar, 50 µm). (C) Calcium concentrations were measured in triplicate using a Calcium LiquiColor test. 
Relative mRNA expression levels of differentiation-associated markers in the control and DLX5-induced MSCs after (D) osteogenic induction, (E) chondro-
genic induction, and (F) adipogenic induction. *P<0.05 and **P<0.01.
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respectively, were inhibited in the cultured cells. In addi-
tion, osteogenic differentiation of MSCs was significantly 
suppressed by DLX5-siRNA, with a decrease in osteopontin 
gene expression compared to the control. In contrast, the 
chondrogenic and adipogenic potential of these cells was unaf-
fected by DLX5-siRNA, as proteoglycans for chondrogenesis 
and neutral lipids for adipogenesis were similarly detected 
by immunohistochemical staining in control cells exposed to 
inductive conditions. These results indicate that DLX5 drives 
the osteogenic differentiation program in MSCs.
Tanshinone IIA is a major active phytochemical that 
is isolated from the roots of S. miltiorrhiza and enhances 
BMP2-stimulated differentiation of myoblasts into osteo-
blasts (23). However, there is little research on the effects of 
tanshinone IIA on the osteogenic differentiation of MSCs. 
To examine the effects of tanshinone IIA on MSCs, DLX5 
not-expressing cells were cultured with tanshinone IIA. Our 
data showed that DLX5 induced by tanshinone IIA activated 
osteogenic marker genes, including osterix, RUNX2 and osteo-
pontin, in cooperation with BMP2, with cell morphologies 
that remained similar to control cells, whereas tanshinone IIA 
suppressed BMP7 gene (chondrogenesis) and C/EBPA gene 
(adipogenesis) expression. These results are in line with previous 
studies showing that DLX5 plays a role in BMP2-induced 
osteogenesis through upregulation of the RUNX2 gene, and that 
it functions as part of the BMP signaling pathway (21,31). In 
addition, these results suggest that tanshinone IIA is involved 
in the BMP2 signaling pathway and DLX5-induced osteogenic 
differentiation. Functional validation with tanshinone IIA was 
carried out by differentiation assays and PCR analysis. MSCs 
with strongly upregulated DLX5, RUNX2, BMP2 and osteo-
pontin genes following tanshinone IIA treatment differentiated 
into osteoblasts and showed significantly increased calcium 
deposition compared to DLX5 not-expressing cells. However, 
a higher concentration of tanshinone IIA (6 µM) decreased 
the osteogenic capacity of MSCs, indicating that osteogenic 
differentiation following DLX5 induction in treated cells is 
tanshinone IIA concentration-dependent (data not shown). 
Additionally, MSCs treated with tanshinone IIA differentiated 
into chondrocytes and adipocytes despite inhibition of BMP7 
and C/EBPA, indicating that these genes may not be essential 
factors for differentiation. Furthermore, DLX5 may play a role 
as an osteogenesis determinant through the upregulation of 
RUNX2 and the downregulation of BMP7 and C/EBPA.
Here, we showed that DLX5 is a specific target of 
BMP2-induced osteogenesis of MSCs, demonstrating that 
DLX5 and BMP2 can contribute to RUNX2-independent regu-
lation of osteogenesis. This indicates that RUNX2 induction 
is not mediated by BMP2 and DLX5 in MSCs as previously 
reported (32). Additionally, we confirmed that RUNX2 is not 
essential for the induction of an osteogenic lineage of MSCs, 
indicating that RUNX2 may function in concert with DLX5 to 
induce osteogenic differentiation by regulating the expression 
of osteogenesis-specific markers such as osteopontin. These 
findings are in agreement with previous results showing that 
DLX5 plays an important role in the activation of osteogen-
esis by regulating BMP-induced RUNX2 (22). Moreover, we 
showed that tanshinone IIA is capable of stimulating DLX5 
expression with BMP2, resulting in osteogenic differentiation 
of MSCs. To the best of our knowledge, we showed for the 
first time that tanshinone IIA can be used in place of DLX5 to 
induce differentiate of MSCs into osteoblasts. Fig. 6 shows a 
schematic model that summarizes the osteogenesis of MSCs 
by the induction of the DLX5 gene using tanshinone IIA. 
Our findings contribute to the development of effective bone 
regeneration therapies for the treatment of bone diseases. 
Furthermore, tanshinone IIA is a chemical compound that 
may be used for the treatment of bone diseases; however, 
Figure 6. Model summarizing osteogenesis in mesenchymal stem cells (MSCs). Distal-less homeobox 5 (DLX5) and DLX5 inducer, tanshinone IIA, promote 
the differentiation of MSCs into osteoblasts by upregulating osteogenesis-related genes.
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our in vitro results require in vivo validation. Additional 
investigations are required for a deeper understanding of the 
upstream and downstream signaling pathways related to other 
osteogenesis-related factors.
In conclusion, our data showed that DLX5 plays a role as 
a master transcription factor in osteogenic differentiation, and 
that tanshinone IIA, coincident with the induction of BMP2, 
synergistically induces osteogenesis by targeting DLX5.
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